- Home
- PFGC vs BBIO Comparison
PFGC vs BBIO Comparison
Compare PFGC & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PFGC | BBIO |
|---|---|---|
| Founded | 1885 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 15.3B |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PFGC | BBIO |
|---|---|---|
| Price | $88.38 | $65.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 23 |
| Target Price | ★ $116.44 | $82.26 |
| AVG Volume (30 Days) | 2.2M | ★ 3.1M |
| Earning Date | 05-04-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $17,619,900,000.00 | $502,076,000.00 |
| Revenue This Year | $15.14 | $85.55 |
| Revenue Next Year | $6.66 | $71.10 |
| P/E Ratio | $91.13 | ★ N/A |
| Revenue Growth | 5.12 | ★ 126.26 |
| 52 Week Low | $68.40 | $28.33 |
| 52 Week High | $109.05 | $84.94 |
Technical Indicators
Market Signals| Indicator | PFGC | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 36.29 | 39.11 |
| Support Level | $83.79 | $61.54 |
| Resistance Level | $97.74 | $68.71 |
| Average True Range (ATR) | 2.55 | 3.09 |
| MACD | -1.00 | -0.28 |
| Stochastic Oscillator | 7.93 | 23.01 |
Price Performance
Historical ComparisonAbout PFGC Performance Food Group Company
Performance Food Group Co , markets and distributes national and company-branded food and food-related products. The company also specializes in distributing candy, snacks, beverages, cigarettes, other tobacco products, health and beauty care products and other items to vending distributors, box retailers, theaters, convenience stores, drug stores, grocery stores, travel providers, and hospitality providers. The company has three reportable segments: Foodservice, Vistar, and Convenience.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.